Introduction
The execution of apoptotic cell death is mediated by caspases, a family of cysteine proteases (Kumar, 2007) . One of the ubiquitously expressed and most evolutionarily conserved mammalian caspase is caspase-2 (Kumar et al., 1992 (Kumar et al., , 1994 Wang et al., 1994; Lamkanfi et al., 2002) . It is also one of the closest mammalian homologues of the Caenorhabditis elegans CED-3, the first-discovered caspase (Kumar et al., 1992 (Kumar et al., , 1994 Yuan et al., 1993; Wang et al., 1994; Lamkanfi et al., 2002) . Despite its conservation and discovery as one of the first mammalian homologues of CED-3, the physiological function of caspase-2 remains controversial. Like CED-3 in C. elegans (Yuan et al., 1993) , the initiator caspase DRONC in Drosophila and caspase-9 in mammals, caspase-2 contains a caspase recruitment domain (CARD) (Kumar et al., 1992; Dorstyn et al., 1999; Kumar and Doumanis, 2000; Degterev et al., 2003; Kumar, 2007) . Caspase-2 activation occurs rapidly in response to diverse apoptotic signals in most cell types (Harvey et al., 1997; Zhivotovsky and Orrenius, 2005; Kumar, 2007) . The CARD plays an essential role in initial caspase-2 oligomerization/activation and the fusion of the caspase-2 prodomain to caspase-3 generates an autoactivating chimeric molecule (Butt et al., 1998; Colussi et al., 1998; Shearwin-Whyatt et al., 2001; Baliga et al., 2004) . Caspase-2 can bind to the CARD-containing molecule RAIDD and data suggest that PIDD, a p53-induced death domaincontaining protein, binds RAIDD and facilitates caspase-2 activation (Shearwin-Whyatt et al., 2000; Tinel and Tschopp, 2004) .
Previous studies have suggested caspase-2 acts upstream of MOMP (Guo et al., 2002; Kumar and Vaux, 2002; Lassus et al., 2002; Paroni et al., 2002; Robertson et al., 2002; Zhivotovsky and Orrenius, 2005) . It has been shown to cause MOMP by activating Bid and Bax (Bonzon et al., 2006) . In the case of Bid, caspase-2 can directly cleave full-length Bid to activated tBid (Guo et al., 2002; Bonzon et al., 2006) . Caspase-2 activation has been implicated in apoptosis in response to a range of signals, including DNA damage, withdrawal of trophic support, heat shock, treatment with chemotherapeutic agents and tumor necrosis factor-related apoptosis-inducing ligand (Kumar, 1995; Troy et al., 2001; Lassus et al., 2002; Panaretakis et al., 2005; Shin et al., 2005; Bonzon et al., 2006; Yeung et al., 2006; Mhaidat et al., 2007) . Caspase-2 has also been shown to associate with CD95 DISC and is activated within this complex but seems not to be essential for CD95-mediated cell death (Lavrik et al., 2006) . The precise function of caspase-2 has remained an enigma as there is no dramatic phenotype observed in Casp2 knockout (KO) mice, apart from a slight increase in the number of oocytes (Bergeron et al., 1998; O'Reilly et al., 2002) . This suggests that the role of caspase-2 in cell death is redundant or is compensated by other caspases. Many of the in vitro caspase activation studies employing cultured cell lines have not been replicated in cells derived from Casp2 KO mice. Cells from Casp2 À/À mice show normal sensitivity to a range of apoptotic stimuli (O'Reilly et al., 2002) . While one study showed that Casp2 null mouse embryonic fibroblasts (MEFs) are resistant to apoptosis induced by heat shock (Bonzon et al., 2006) another report has contradicted this finding (Milleron and Bratton, 2006) . Thymocytes from double KO (DKO) of Casp2 and 9 mice show normal sensitivity to apoptosis induced by various agents suggesting that they do not compensate for the loss of each other . In addition, B and T lymphocytes from double knockout (DKO) animals were shown to be sensitive to many apoptotic stimuli .
There is limited evidence, based largely on nonspecific or partial caspase-2 inhibition, that caspase-2 may play a role in apoptosis induced by cytoskeletal disruption. In order for cells to maintain cellular integrity, a dynamic balance must exist between actin and microtubule filaments. Actin maintains cellular shape, form cytoplasmic projections, regulates motility and facilitates signal transductions (Gourlay and Ayscough, 2005; Shi and Rothfield, 2006) . Microtubules are involved in intracellular transport and play a role in regulation of mitotic spindle. Inhibition of actin polymerization (for example by cytochalasin D (cyto D)) or actin stabilization leads to apoptosis (Gourlay and Ayscough, 2005) . Similarly, depolymerization or stabilization of microtubules by drugs such as vincristine (Vinc) and paclitaxel (Pacl), also results in death (Wang et al., 2004) . Inhibition of caspase-2 by zVDVAD (not a specific inhibitor of caspase-2) prevented lovastatin-induced apoptosis by reducing alterations to cytoskeletal F-actin (Kong and Rabkin, 2005) . Lovastatin is an inhibitor of HMG-CoA reductase, an important enzyme in the mevalonate pathway responsible for the synthesis of cholesterol and protein isoprenylation, which includes the isoprenylation of Ras family of GTPases, which are involved in multiple signalling pathways including the control of cell architecture (Green, 2005; Wennerberg et al., 2005) . A correlation between low levels of caspase-2 and resistance to apoptosis induced by prednisolone, Vinc and asparagines has been shown in acute lymphoblastic leukaemia (ALL) patients suggesting that caspase-2 might be required for apoptosis induced by these drugs (Holleman et al., 2005) .
To avoid potential problems associated with cultured cell lines, overexpression by transfection and knockdown using small interfering RNA (siRNA), in this study we have used early passage MEFs derived from Casp2 À/À and wild-type littermates to assess possible context-dependent function of Casp2 in apoptosis induced by various cytotoxic insults. We report here that caspase-2 plays a specific role in apoptosis induced by cytoskeletal disruption.
Results
Caspase-2 is required for ZA-induced cell death of MEFs To investigate the importance of caspase-2 in stressinduced cell death, we treated early passage MEFs from wild-type (WT) or Caspase2 À/À (Casp2
) mice with various cytotoxic drugs. WT and Casp2 À/À MEFs were sensitive to apoptosis induced by etoposide, ethylene glycol tetraacetic acid (EGTA), staurosporine and serum deprivation (Figure 1a) . Interestingly, we found that Casp2 À/À MEFs were significantly less sensitive to treatment with zoledronic acid (ZA) compared to WT cells (Figure 1a) . We tested the sensitivity of WT MEFs to a titration of ZA concentrations and found that treatment with 12.5 mM ZA induced over 90% death within 72 h (Figure 1b ). In contrast, over 70% of the Casp2 À/À cells were viable when treated with 12.5 mM ZA and greater than 60% of the Casp2 À/À cells retained viability when treated with 25 mM ZA (Figures 1a and b) . Interestingly, immortalized, factor-dependent myeloid cells from Casp2 À/À mice were also partially resistant to apoptosis induced by ZA (data not shown). Furthermore, cultured cell lines in which Casp2 was knocked down by siRNA showed similar effects (data not shown). These data indicate that caspase-2 is required for cell death induced by ZA.
We next assessed caspase activity in response to ZA by measuring cleavage of fluorogenic substrates VDVAD-AMC and DEVD-AMC. Consistent with reduced apoptosis, caspase activity was significantly lower in Casp2 À/À MEFs following ZA treatment (Figures 2a and b) . We also observed a decrease in the processing of caspase-3 in Casp2 À/À MEFs compared to WT (data not shown). As ZA can inhibit cell adhesion signalling, the ability of caspase-2 to mediate cell death induced by loss of adhesion (anoikis) was also tested by plating cells onto poly-HEMA-coated dishes to prevent cell attachment. No difference in the viability of WT and Casp2 À/À MEFs was seen suggesting that caspase-2 is unlikely to be involved in cell death caused by anoikis (data not shown). (Figures 3a and b) . In response to each of these treatments, significantly more Casp2 À/À MEFs were viable compared to WT MEFs. As previously seen, treatment with ZA induced over 70% death in WT MEFs compared to only 35% death in Casp2 À/À MEFs (Figures 3a and b) .
We then assessed caspase activity following treatment with Vinc, Pacl and cyto D. In response to all treatments, we found that Casp2 À/À MEFs displayed significantly lower VDVADase and DEVDase activity compared to caspase activity in WT MEFs (Figures 2a  and b ). Interestingly we also noted that untreated Casp2 À/À MEFs had consistently lower intrinsic activity on both VDVAD-AMC and DEVD-AMC substrates compared to WT (Figures 2a and b) .
We assessed the kinetics of cell death induced by each of these cytoskeletal-disrupting agents over 24 or 72 h ( Figure 3c ). As expected, Casp2 À/À MEFs displayed a significant delay in apoptosis in response to ZA compared to WT MEFs ( Figure 3c ). In addition, Casp2 À/À MEFs showed significant resistance up to 24 h following treatment with Vinc and cyto D and up to 72 h treatment with Pacl ( Figure 3c ). In contrast, cell death of WT MEFs is detected as early as 1 h following exposure to Vinc and cyto D, and from 24 h onwards when exposed to Pacl and ZA.
To assess changes in cellular architecture and microtubule arrangement in response these cytoskeletaldisrupting drugs, we immunostained WT and Casp2
À/À
MEFs for tubulin (a tubulin) and actin (phalloidin). In WT and Casp2 À/À MEFs, we found that treatment with Vinc and cyto D, effectively caused rapid disruption of cytoskeleton within 1 h, at a time when there is no visible apoptosis or loss of cell viability (Figures 4a and b) . Even though cells exhibited the same extent of cytoskeletal damage in response to these drugs, viability of Casp2 À/À MEFs was significantly higher than that of WT MEFs (Figure 3a ), indicating that caspase-2 mediates its effect downstream of cytoskeletal damage. cytochalasin D (Cyto D), 50 mg ml À1 vincristine (Vinc) for 24 h, 100 mM paclitaxel (Pacl) for 48 h and 50 mM zoledronic acid (ZA) for 72 h at 37 1C. The activity of caspase-2 (a) and caspase-3 (b) was assessed by cleavage of VDVAD and DEVD fluorogenic substrates in whole cell lysates. Activity of these enzymes is expressed as relative fluorescence units (RFU). Data ( ± s.e.m.) were derived from six experiments using different batches of MEFs. Asterisk (*) represents P-values o0.05 obtained using Student's t-test of comparing WT versus Casp2 À/À MEFs.
Casp2
À/À MEFs survive following drug removal To determine the long-term effect of cytoskeletal disruption in Casp2 À/À MEFs, we tested the viability of cells 48 h following removal of each cytoskeletaldisrupting drug. Cytoskeletal disruption induced rapid apoptosis of WT MEFs, which could not be rescued by drug removal (Figure 5a ). In contrast we found that following removal of ZA, Vinc and Pacl, a significant proportion of Casp2 À/À MEFs continued to grow and cells displayed greater than 65% viability compared to less than 30% viability of WT MEFs (Figure 5a ). Following the removal of cyto D, while cell viability was reduced, we still detected greater than 40% survival rate in Casp2 À/À MEFs compared to 20% in WT cells (Figure 5a ). We also tested the clonogenic potential of drug-treated WT and Casp2 À/À MEFs. Following treatment with various drugs, cells were seeded and left in culture for 14 days. As shown in Figures 5b and c, while drug-treated WT cells failed to generate colonies, Casp2 À/À MEFs showed significant clonogenic potential. These results indicate that in the absence of caspase-2, MEFs can be rescued from eventual apoptosis and survive long term following cytoskeletal disruption.
Bid cleavage is delayed in Casp2
À/À MEFs As caspase-2 has been shown to activate Bid upstream of MOMP (Guo et al., 2002; Kumar and Vaux, 2002; Lassus et al., 2002; Paroni et al., 2002; Robertson et al., 2002; Zhivotovsky and Orrenius, 2005) , we tested if this is how caspase-2 may be functioning following cytoskeletal disruption. We investigated Bid cleavage and activation in Casp2 resistance to apoptosis induced by cytoskeletal disruption.
Cytoskeletal disruption-induced apoptosis requires RAIDD and PIDD Previous studies have shown that one of the mechanisms of caspase-2 activation involves Piddosome, a complex containing RAIDD and PIDD (Tinel and Tschopp, 2004 ). Therefore we examined whether cytoskeletal disruptors induce apoptosis via Piddosome formation. While only partial knockdown of RAIDD was achieved, we could significantly knockdown PIDD in MEFs by transfecting specific siRNAs (Figure 6b ). Following knockdown, WT MEFs were treated with cytoskeletal disruptors and apoptosis assessed by Annexin V staining. Knockdown of either RAIDD or PIDD in MEFs (Figure 6b ) showed significantly reduced apoptosis with all drug treatments (Figure 6c ). These data indicate that Piddosome components are required for apoptosis induced by cytoskeletal disruptors.
Bax translocation and cytochrome c release are delayed in Casp2 À/À MEFs We next examined Bax translocation in WT and Casp2
À/À
MEFs treated with each of the cytoskeletal disruptors.
Cells were immunolabelled for active Bax using the 6A7 antibody and mitochondria were marked with MitoTracker Red. Since the 6A7 antibody was used, no active Bax fluorescence was detected in untreated MEFs (Figure 7a ). Bax is normally localized to the cytoplasm and in response to apoptotic stimuli, it is recruited to the mitochondria where it plays a role in MOMP (Antignani and Youle, 2006) . Following drug treatment, WT MEFs exhibited Bax 6A7 immunofluorescence, which was punctate, consistent with mitochondrial translocation of Bax (Figure 7a ). Punctate staining of Bax was also observed in Casp2 À/À MEFs following drug treatment, but we noted that fewer cells exhibited Bax 6A7 immunofluorescence compared to WT MEFs (Figure 7a) . We counted the number of Bax 6A7 immunostained cells and observed a significant reduction in the number of Casp2 À/À MEFs that exhibited a Bax-punctate staining pattern, compared to WT cells (Figure 7b ). Bax activation was also quantified by fluorescence-activated cell sorting (FACS) analysis, which showed that following drug treatment, Casp2
MEFs had less active Bax compared to WT MEFs, as indicated by the reduced fluorescence shift from untreated cells (Figure 7c ).
To examine cytochrome c release in WT and Casp2
MEFs treated with the various drugs, we carried out cell fractionation experiments and immunoblotted cytosolic fractions for cytochrome c (Figure 8a ). We noted reduced cytosolic cytochrome c in Casp2 À/À MEFs following drug treatment compared to WT (Figure 8a ). To confirm our fractionation studies we also assessed cytochrome c release from mitochondria by immunostaining cells. As expected cytochrome c exhibited a punctate staining pattern in untreated MEFs that co-localized with MitoTracker Red, consistent with localization to the mitochondria (Figure 8b ). Treatment of WT MEFs with each cytoskeletal-disrupting drug resulted in diffuse cytochrome c staining throughout the cytoplasm indicative of its release from the mitochondria. In contrast, cytochrome c staining was still punctate and localized to mitochondria in the majority of Casp2 À/À MEFs following drug exposure (Figure 8b ). We calculated the number of cells with diffuse cytochrome c staining and noted a significant reduction of cytosolic cytochrome c in Casp2 À/À MEFs (Figure 8c ), indicating that cytochrome c had not been released in a large number of Casp2 À/À cells. Similar results were seen when cytochrome c release was quantified by FACS analysis. We observed that Casp2 À/À MEFs had significantly reduced cytochrome c released into cytosol, compared to WT MEFs (Figure 8d ). The reduced cytochrome c release in Casp2 À/À MEFs suggests that the induction of MOMP is significantly delayed in the absence of caspase-2.
Discussion
Despite numerous studies, the function of caspase-2 has remained enigmatic. In this study, using Casp2 deficient ) and Cyto D (10 mg ml
À1
) for 1 h and stained for tubulin, using anti-a tubulin antibody (green) (a) or for actin using phalloidin (red) (b). Cells were co-stained with Hoechst (blue).
Cytoskeletal damage induces apoptosis via caspase-2 LH Ho et al Figure 5 Higher survival rate in Casp2 À/À mouse embryonic fibroblasts (MEFs) following withdrawal of cytoskeletal disruptors. MEFs were treated with 50 mM zoledronic acid (ZA) for 72 h, 50 mg ml À1 vincristine (Vinc) and 10 mg ml À1 cytochalasin D (Cyto D) for 24 h and 100 mM paclitaxel (Pacl) for 48 h. All drugs were removed by washing out with culture medium and MEFs were allowed to incubate for a further 48 h in fresh medium. (a) Viability was assessed by Trypan blue staining. Data ( ± s.e.m.) were derived from six experiments using different batches of MEFs. (b and c) Clonogenic assay; MEFs were treated with the indicated drugs. 500 cells per well were plated into six-well dishes and cultured for 14 days. Colonies of more than 10 cells were counted (b) and images of proliferating cells on surfaces of the wells are shown at Â 10 magnification (c). Results are expressed as data (±s.e.m.). Asterisk (*) represents P-values o0.05 obtained using Student's t-test of comparing wild-type (WT) versus Casp2 À/À MEFs.
cells from KO mice, we have demonstrated a role for caspase-2 in cell death induced by cytoskeletal disruption. Stable cellular morphology is promoted through a dynamic balance of counteracting actin and microtubule filaments and ongoing maintenance of the cytoskeleton is essential to prevent apoptosis in cells (Martin and Vouri, 2004; Gourlay and Ayscough, 2005) . Our study demonstrates that, despite having the same extent of damage to cellular architecture, Casp2 À/À MEFs exhibit significant resistance to death compare to WT MEFs following exposure to cytoskeletal disruptors. Furthermore this caspase-2 mediated death occurs via Piddosome, activation and cleavage of Bid, Bax translocation and release of cytochrome c. We have demonstrated that these processes are significantly delayed in the absence of caspase-2.
Many cytoskeletal damaging agents such as ZA, taxol, cyto D and Vinc are effective chemotherapeutic drugs against a variety of cancers (Bhalla, 2003) . These drugs can effect many cellular events including cell cycle progression and cell motility and subsequently kill cells by activating the apoptotic pathway. However, the precise mechanism of how cytoskeletal damaging drugs function to induce apoptosis is not well understood. Recent studies have casually implicated caspase-2 in cell death induced by cytoskeletal disruption. For example, an association between caspase-2 and RhoB has been suggested in apoptosis induced by lovastatin, which acts by inducing depolymerization of F-actin filaments (Kong and Rabkin, 2005) . Our data also indicate a role for caspase-2 in ZA-induced apoptosis. ZA is a nitrogen Bisphosphonate used for the treatment of cancerinduced bone disease such as multiple myeloma and bone metastasis secondary to breast cancer (Theirault, 2003; Green, 2005) . ZA exerts its effect by inhibiting farnesyl diphosphate synthase, a key enzyme in the mevalonate pathway, the same pathway disrupted by lovastatin. The inhibition of farnesyl diphosphate synthase prevents the post-translational isoprenylation of proteins, such as the Ras family of GTPases. This in turn affects a variety of signalling pathways related to cell morphology, adhesion, motility, growth and cancer cell metastasis. Given that Casp2 À/À MEFs display resistance to ZA-induced death, it is likely that loss of caspase-2 may effect Rho signalling.
Our results indicate that caspase-2 also functions in apoptosis in response to a range of cytoskeletal damaging drugs other than ZA. In support of this, an independent study has shown that docetaxel-induced apoptosis is dependent on caspase-2 activation (Mhaidat et al., 2007) . Paclitaxel (Pacl) is a member of the Taxanes family and has a similar mode of action to docetaxel, in that it functions as a microtubule-stabilizing agent (Mhaidat et al., 2007) . In contrast, Vinc acts to depolymerize microtubule filaments, whereas cyto D inhibits polymerization of actin filaments and has been shown to activate p53-dependent death (Bhalla, 2003) . In addition, there is a correlation between low levels of caspase-2 and resistance to apoptosis in ALL patients treated with drugs such as Vinc (Holleman et al., 2005) . Together with our findings these studies further enforce a role for caspase-2 in cytoskeletal damage-induced cell death.
One of the mechanisms for caspase-2 activation is via the formation of Piddosome (Tinel and Tschopp, 2004) . We found that knocking down either RAIDD or PIDD in WT MEFs resulted in significant inhibition of apoptosis by cytoskeletal-disrupting drugs, indicating involvement of Piddosome. It has been previously shown that active caspase-2 mediates cleavage and activation of Bid (Guo et al., 2002; Bonzon et al., 
2006
). Truncated tBid then translocates to the mitochondria, mediates MOMP and activates the Apaf-1/ caspase-9 pathway. Bax activation which occurs downstream of caspase-2 activation may also be involved in MOMP. Since Bid is a known caspase-2 substrate (Guo et al., 2002; Bonzon et al., 2006) , it is likely that Bid mediates induction of MOMP by caspase-2. As shown in our study, in the absence of caspase-2, both Bid cleavage and Bax activation were inhibited following cytoskeletal damage. These data suggest that caspase-2-mediated apoptosis involves both Bid and Bax activation. However, we do not yet know whether both are essential to mediate cell death induced by cytoskeletal damage. Bax activation downstream of caspase-2 activation in stress-induced cell death has been previously shown (Lassus et al., 2002) and Bid cleavage by caspase-2 has been shown to occur in response to heat shock, which may also cause cytoskeletal damage (Bonzon et al., 2006) . Thus it is likely that activation of both Bid and Bax play a role in caspase-2-dependent cell death induced by cytoskeletal disruption. In summary, the findings presented here indicate a key function for caspase-2 in mediating cell death induced by cytoskeletal disruption. Although we do not yet know how cytoskeletal disruption links to caspase-2 activation, our data provide a mechanism for cytoskeletal damage-induced death via Piddosomemediated caspase-2 activation and downstream activation of Bid and Bax, which would lead to MOMP, release of cytochrome c and activation of the Apaf-1/ caspase-9 apoptosome.
Materials and methods

Cell culture
Casp2 KO mice were kindly provided by Dr David Vaux. These animals were originally derived from 129Sv ES cells and have been backcrossed over 10 times to C57BL6 mice (O'Reilly et al., 2002) . Immortalized, factor-dependent myeloid cells from Casp2 À/À mice were kindly provided by Dr Paul Ekert . MEF isolated from 14.5-day-old embryos of WT and Casp2 À/À littermates were cultured in Dulbecco's modified Eagle's medium (DMEM; SAFCS Biosciences, Lenexa, Kansas, USA) supplemented with 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 100 mM penicillin/streptomycin (CSL Biosciences, Parkville, VIC, Australia) and 10% fetal calf serum (JRH Biosciences). Cells were cultured in a humidified incubator at 37 1C with 5% CO 2 .
Cytoskeletal-disrupting drugs
MEFs were treated with either 50 mM ZA over 72 h, 100 mM Pacl for 48 h, 50 mg ml À1 Vinc for 16 h or with 10 mg ml
À1
, cyto D for 16 h. ZA was a gift of Dr Andrew Zannettino, whereas other drugs were purchased from Sigma (St Louis, MO, USA).
Cellular fractionation and immunoblotting
Cells were treated with the cytoskeletal-disrupting drugs for 6 h and then harvested in buffer A (20 mM HEPES-KOH, pH 7.5, 100 mM KCl, 2.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 250 mM sucrose, 0.025% digitonin) supplemented with protease inhibitors (Roche, Indianapolis, IN, USA). Cells were lysed on ice by homogenization and cell lysis confirmed by Trypan blue uptake. Cell debris was pelleted at 3000 g, 10 min at 4 1C, and cytosolic fractions separated by centrifugation at 16 000 g, 20min at 41C. Proteins from fractionated or unfractionated whole cell lysates were resolved on 12-15% SDS-polyacrylamide gel electrophoresis (PAGE), transferred to polyvinylidine difluoride membrane (Polyscreen Dupont, Boston, MA, USA). Membranes were blocked in 5% skim milk-sodium phosphate buffer with NaCl and Tween 20 (PBST) and immunoblotted with anti-cytochrome c mouse antibody (clone 7H8.2C12; BD Biosciences Pharmingen), antiBax rabbit polyclonal (BD Biosciences Pharmingen), anti-Bid rabbit antibody (BD Biosciences Pharmingen) or mouse antib-actin (Cell Signalling, Danvers, MA, USA). Secondary antibodies conjugated to alkaline phosphatase were used to detect protein by enhanced chemifluorescence (ECF) substrate (Amersham Biosciences, Piscataway, NJ, USA) using the Typhoon 9410 Variable Mode Imager (Molecular Dynamics, Piscataway, NJ, USA) and Image Quant software (Amersham Biosciences). Protein detection using secondary horseradish peroxidase-conjugated antibodies (Chemicon, Temecula, CA, USA) was performed with ECL Plus western blot detection system (Amersham Biosciences).
Immunocytochemistry and confocal imaging Cells were seeded onto coverslips and treated with cytoskeletal disruptors, incubated with 100 nM of MitoTracker Red (Molecular Probes) for 30 min at 37 1C, fixed with 4% paraformaldehyde for 15 min, permeabilized with 1% 3-[(3-cholamidopropyl)DimethylAmmonio])À/À Propanesulfonate (CHAPS) at room temperature (RT) for 10 min, blocked in 1% bovine serum albumin (BSA) phosphate-buffered saline (PBS) for 30 min at RT and stained with primary antibodies in blocking buffer as follows: 1 mg ml À1 anti-cytochrome c mouse antibody (clone 6H2.B4; BD Biosciences Pharmingen) or antiBax mouse antibody (clone 6A7; BD Biosciences Pharmingen) at 4 1C overnight. Cells were washed in PBS and stained with Alexa 488-conjugated secondary antibody (Molecular Probes) for 1 h at RT. Bax-6A7-positive-stained cells and cells exhibiting diffuse cytosolic cytochrome c staining were counted and a total of 300 cells counted per treatment in three separate experiments. Results were pooled and expressed as percentage percentage Bax-positive cells or percentage cells with cytosolic cytochrome c. In some experiments cells were stained with either a-tubulin or Phalloidin Alexa 549 (Molecular Probes) antibody. Hoechst-33342 (Molecular Probes) was used at 0.4 mg ml
À1
. Coverslips containing stained cells were inverted onto microscope slides with a drop of Antifade solution (1% propylgalate, 87% glycerol). Fluorescence images were captured using a confocal microscope (Radiance 2100, Bio-Rad, Hercules, CA, USA) or an epifluorescence microscope (model BX51, Olympus) and a camera (U-CMAD3/CVM300, Olympus). Cells were visualized under Â 40 UPLAPO objective lens with numeric operture (NA) ¼ 0.8. Images were processed using Olysia BioReport Software (Olympus). Fluorescent images were merged manually using Adobe Photoshop software.
Assays for cytochrome c release and Bax activation by FACS Cytochrome c release assays were performed as previously described (Waterhouse and Trapani, 2003) . Briefly, cells were treated with disruptors for 12 h, fixed in paraformaldehyde (4% in PBS) for 20 min at RT, washed in PBS and incubated in blocking buffer (3% BSA, 0.05% saponin in PBS) for 1 h. Cells were incubated overnight with anti-cytochrome c antibody (clone 6H2.B4) in blocking buffer, washed and incubated for 1 h at RT with mouse Alexa Fluor-488-conjugated secondary antibody (Molecular Probes). Cells were analysed by FACS with the number of cells with low fluorescence indicative of cytochrome c release. For Bax activation, assays were carried out as described in Handrick et al. (2006) and Kepp et al. (2007) . Briefly, treated cells were washed in PBS and permeabilized in 0.1% Triton X-100 in PBS for 10 min at RT, blocked in 10% fetal calf serum in PBS for 20 min at RT, washed and incubated with anti-Bax mouse antibody (clone 6A7) for 1 h at RT. Cells were then washed, incubated with mouse Alexa Fluor-488-conjugated secondary antibody for 30 min in the dark at 41C. Cells were washed in blocking buffer and resuspended in 100 ml PBS. Bax (6A7) fluorescence was quantified by FACS where Bax activation was detected as a fluorescence shift compared to untreated cells.
Viability, cell death and drug withdrawal assays Following treatments, cells were harvested by trypsinization and cell viability and apoptosis determined by Trypan blue and/or Annexin V (Roche) staining. Results were pooled from three independent experiments for each treatment. For proliferation analysis, 3 Â 10 5 WT and Casp2 À/À MEFs were plated onto 6 Â 60 mm culture dishes in DMEM with 10% FBS. Cells were harvested and counted everyday up to 6 days. For drug withdrawal assays, cells were treated with Vinc or cyto D for 24 h, Pacl for 48 h or with ZA for 72 h, washed and fresh incubating medium was added. Cells were cultured at 37 1C for a further 48 h and viability assessed by Trypan blue dye exclusion.
Caspase assays
Caspase assays were carried out in a buffer (25 mM HEPES, pH 7.4, 10% sucrose, 0.1% CHAPS, 1 mM EDTA, 10 mM DTT) supplemented with protease inhibitors (Roche). Lysates were prepared in assay buffer and 30 mg incubated with 100 mM of either VDVAD-AMC (California peptide research) or DEVD-AMC (Enzyme System Products, Livermore, CA, USA) substrate in a total volume of 50 ml at 371C for 60 min. Fluorescence was analysed on a FLUOstar Optima Luminescence Spectrometer (BMG Labtech, Durham, NC, USA; excitation 355 nm, emission 460 nm). Results from three independent experiments were expressed as relative fluorescence units.
PIDD AND RAIDD knockdown
MEFs were transfected with either PIDD siRNA (sense-GCU UAUGGCUGCUCUUUGU, CCAUGCAGGUAGUGCAU AU, CACACCUGAAGAACGUAAA; Santa Cruz sc-44657) or RAIDD siRNA (sense-CAGACCAGCAGAUUAACCA, GAAGACUGCGCUGUUGUAA, GAGUGGAGCAAGA UUGAUA; Santa Cruz SC-37388) for 72 h with Gene Eraser (Stratagene, La Jolla, CA, USA). Scramble siRNA was used as control (Santa Cruz, Santa Cruz, CA, USA). Following transfection, cells were treated with cytoskeletal disruptors and viability assessed by annexin V staining and flow cytometry. Knockdown was assessed by western blot of cell lysates, using anti-PIDD (sc-32161, Santa Cruz) and anti-RAIDD (sc-7880 Santa Cruz) antibodies.
Clonogenic assay
Cells were treated with the cytoskeletal-disrupting drugs as described, washed and then plated (500 cells per well) in sixwell plates for 14 days. Colonies were fixed with cold methanol for 10 min, stained with 0.1% toluidine blue in 1% formaldehyde for 30 min, washed with PBS and counted. The colonies with >10 cells were counted.
Abbreviations
Casp2, caspase-2; cyto D, cytochalasin D; KO, knockout; MEFs, mouse embryonic fibroblasts; MOMP, mitochondrial outer membrane permeabilization; Pacl, paclitaxel; Vinc, vincristine; ZA, zoledronic acid.
